(Prostate Cancer) WT1 Cancer Vaccine Clinical Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
In immune cell therapy clinics, the term "WT1" frequently appears. What exactly is WT1? It is one of the genes responsible for causing Wilms' tumor (a kidney tumor), and WT1-generated mRNA (WT1 mRNA) has also been detected in acute myeloid leukemia and solid cancers. In the case of leukemia, complete remission may be achieved through chemotherapy, but microscopic residual leukemia cells may remain in the body — in this context, WT1 mRNA testing is a commonly used monitoring method. Researchers subsequently explored whether targeting WT1 as a tumor marker could enable the immune system to recognize and attack cancer cells, giving rise to numerous clinical research programs. The following is one such initiative:
Clinical Trial Name: WT1-WT10 peptide vaccine combined with detoxified Bordetella pertussis cell components — Phase I/II clinical trial (W10TR-PRO1)
Regimen: WT1-W10 peptide 3.0 mg/300 μl + detoxified Bordetella pertussis 5×10⁸ cells/100 μl, administered once weekly. Target enrollment: 69 patients.
Eligibility criteria:
- Patients with PSA-confirmed prostate cancer relapse (further stratified by prior chemotherapy history)
- HLA type must be one of: HLA-A*24:02, A*02:01, or A*02:07
- Cr ≤ 3.0 mg/dL, BUN ≤ 25 mg/dL
- AST (GOT) ≤ 105 U/L, ALT (GPT) ≤ 120 U/L
- Neutrophils ≥ 1,500/mm³, platelets ≥ 75,000/mm³, Hb ≥ 8.0 g/dL
Note: Even if the above criteria are met, enrollment is subject to review and approval by the sponsoring research institution. Clinical trials are not standard treatments; they are research studies conducted to evaluate whether a given approach is effective. Both efficacy and adverse events represent inherent risks.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Recruiting institution: Kochi University Faculty of Medicine, Cancer Vaccine Therapy Research Network Central Office
Source: https://rctportal.niph.go.jp/detail/jr?trial_id=jRCTs061180084
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4